Department of Laboratory Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Thorac Cancer. 2022 Jul;13(14):2041-2049. doi: 10.1111/1759-7714.14486. Epub 2022 May 27.
The aim of this study is to evaluate the prognostic value of the modified Glasgow prognostic score (mGPS) in advanced esophageal squamous cell carcinoma (SCC) patients.
The study enrolled 311 patients with advanced esophageal SCC from January 2012 to December 2018. Univariate and multivariate analyses were calculated by the Cox proportional hazards regression model in advanced esophageal SCC patients. The Kaplan-Meier method was used to evaluate the ability of the mGPS for survival rates. Propensity score-matched (PSM) analysis was carried out to balance imbalanced variables.
The Cox proportional hazards analysis showed that factors including M stage, ECOG, mGPS group, and sex were identified as independent predictors. The mGPS presented a good level of overall survival (OS) prediction with a risk-adopted classification for advanced esophageal SCC patients. The survival rates in advanced esophageal SCC patients with mGPS 0, 1, and 2 were 18.8%, 8.4%, and 4.2%, respectively (p < 0.001). Moreover, before and after PSM, the mGPS was associated with 3-year survival rates of advanced esophageal SCC patients in the Kaplan-Meier survival analysis. In addition, the mGPS for OS prediction demonstrated better performance than sex and ECOG score. The area under curve (AUC) of the mGPS combined with M stage for the prognosis of advanced esophageal SCC was 0.677 (0.592-0.763).
The mGPS is a cost-effective, accessible tool capable of prognosticating in this cohort. It could be a useful surveillance system of prognosis in advanced esophageal SCC patients.
本研究旨在评估改良格拉斯哥预后评分（mGPS）在晚期食管鳞癌（SCC）患者中的预后价值。
本研究纳入了 2012 年 1 月至 2018 年 12 月期间的 311 例晚期食管 SCC 患者。采用 Cox 比例风险回归模型对晚期食管 SCC 患者进行单因素和多因素分析。采用 Kaplan-Meier 法评估 mGPS 对生存率的预测能力。采用倾向评分匹配（PSM）分析来平衡不平衡变量。
Cox 比例风险分析表明，M 分期、ECOG、mGPS 组和性别等因素被确定为独立预测因素。mGPS 对晚期食管 SCC 患者的总体生存率（OS）具有较好的预测水平，并对风险进行了分类。晚期食管 SCC 患者的 mGPS 0、1 和 2 组的总生存率分别为 18.8%、8.4%和 4.2%（p<0.001）。此外，在 PSM 前后，Kaplan-Meier 生存分析显示 mGPS 与晚期食管 SCC 患者的 3 年生存率相关。此外，mGPS 对 OS 的预测性能优于性别和 ECOG 评分。mGPS 联合 M 分期对晚期食管 SCC 预后的 AUC 为 0.677（0.592-0.763）。
mGPS 是一种经济有效的、可获得的工具，能够在本队列中进行预后预测。它可能是晚期食管 SCC 患者预后监测的有用系统。
